Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Windlas Biotech Ltd - 543329 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyWindlas Biotech Ltd 2CIN NO.L74899UR2001PLC033407 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY APLUS 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ananta Narayan Panda Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Komal Gupta Designation: CEO and CFO EmailId: [email protected] Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Windlas Biotech Ltd - 543329 - Compliance Certificate In Terms Of Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On March 31, 2024
Compliance Certificate in terms of Regulation 40(9) of the SEBI LODR Regulations, 2015 enclosed for the year ended March 31, 2024. Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 Windlas Biotech Ltd - 543329 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate for the Quarter ended March 31, 2024 under Regulation 74(5) of the SEBI DP Regulations, 2018 Windlas Biotech Ltd - 543329 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period From April 01, 2023 To March 31, 2024
Compliance Certificate for the period beginning from April 01, 2023 to March 31, 2024 under Regulation 7(3) of SEBI LODR Regulations, 2015 Windlas Biotech commissions injectables facility in Gurugram, shares up
The launch of the injectables facility marks the company's entry into dosage forms such as ampoules, liquid vials, and lyophilized vials Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on "Windlass Biotech Limited commissions its state of the art Injectable Facility"